In this study we evaluated the effects of a combination treatment with RT to the brain and anti-PD-1 inhibitors (RT-ICI) applied concurrently or non-concurrently in a cohort of 93 patients with 319 brain metastases from different cancer types. Here, PDCD1 is linked to cancer.